Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
Revolution Medicines to Showcase Progress Across RAS Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research Annual Meeting
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS G12V-Selective Inhibitor
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
American Uranium Expands its Lo Herma ISR Uranium Project in Wyoming's Powder River Basin as Company Secures Strategically Located Uranium Mineral Rights and Stakes Additional Mining Claims
